- Exclusive agreement with Medlive, a pharmaceutical and health
products distributor with network of over 3,000 clinics and
hospitals in southern Brazil
- Company's medical cannabis products will be marketed through
Medlive network of doctor offices, clinics, hospitals and
governmental institutions
- Medical education, marketing activities and sales are planned
to start in Q3 2020
- Brazil represents the largest
addressable market in Latin
America with a population of approximately 212 million
TORONTO, April 30, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX:
KHRNF), (Frankfurt: A2JMZC), a
vertically integrated cannabis leader with core operations in
Latin America and Europe, announces that it has entered into an
exclusive agreement with Medlive, a leading marketer and
distributor of pharmaceutical products to clinics, hospitals and
pharmacies in southern Brazil.
Through this agreement physicians in Medlive's extensive network
will receive medical education and training related to Khiron
products.
"Brazil represents one of the
most important markets in Latin
America, with its massive population and its acceptance of
medical cannabis. Together with Medlive we are now positioned to
begin educating health professionals and driving prescriptions for
our medical cannabis products, and ultimately focus on our
objective to help patients in Brazil who can benefit from medical cannabis,"
comments Alvaro Torres, Khiron CEO
and director. "Medlive is recognized as an important medical
marketing organization in the region and we could not have a better
partner to help us achieve these goals."
On November 29th, 2019 Khiron announced it had
received authorization from the Colombian Technical Quotas Group
("TQG") for the commercialization of medical use high THC cannabis
for domestic and export purposes, including to Uruguay. On
February 7th, 2020 the
Company announced authorization from the Brazilian Health
Regulatory Agency (ANVISA) for Khiron medical cannabis product to
be imported for use on an individual patient basis.
The medical cannabis market in Brazil is anticipated to grow to 3.4 million
patients and a market of US$1.4
Billion within three years, including serving patients with
chronic pain conditions (Source: New Frontier Data 2017). Further,
total requests for medical cannabis have tripled since 2015
(Source: ANVISA) and today, approximately 1,100 physicians are now
prescribing medical cannabis to their patients.
"With the rapid globalization of legalized medical cannabis,
including here in Brazil, there is
an important need to bring product education and information to the
country's health professionals. When medical professionals think of
medical cannabis here, they think of Khiron. Khiron was the
best choice to have as a partner, and to bring their highly
regarded product research and development expertise to our health
network," comments Adriana Marques,
Medlive Managing Director.
About Medlive
Medlive is a leader in the distribution
of medical and hospital products in the south of Brazil, serving more than 3,000 hospitals and
clinics in the public and private sectors. Medlive
delivers efficient, effective and agile results through a wide
portfolio of medicines and nutritional products, and with solutions
that are applied across the supply chain for conditions including
cancer treatments and clinical nutrition, among others.
Medlive is a committed commercial partner, understanding needs
and with technical and scientific knowledge in the areas of
pharmacology, nursing and nutrition that make the company an
important resource in the distribution of medicine products. The
company is able to move at speed to support the healthcare
community in the south and southeast regions, and with capacity for
the entire Brazilian territory. Visit http://medlive.com.br
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is the dominant integrated medical cannabis company in
Latin America. Khiron has core
operations in Latin America, along
with activity in North America and
Europe, and is licensed in
Colombia for the cultivation,
production, domestic distribution, and international export of both
tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
The Company delivers best in class regulatory compliance, has the
first approved line of CBD cosmetic products on shelf
in Colombia, and is fully authorized to manufacture high- and
low-THC medical cannabis, and to fill prescriptions for low-THC
medical cannabis in the country.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-signs-exclusive-agreement-with-medlive-a-distributor-serving-3-000-clinics-and-hospitals-in-brazil-301050475.html
SOURCE Khiron Life Sciences Corp.